BridgeBio Pharma

Oct 06, 2020

MyoKardia Buyout: BMS expands its cardiovascular portfolio for USD 13.1 Billion  Bristol Myers Squibb has bounty years in a go with its shares skyrocketing as it decides to go on an acquisition spree.  BMS has announced to acquire MyoKardia, a pharmaceutical company leveraging precision medicine to ...

Aug 07, 2020

The Hereditary Transthyretin Amyloidosis (hATTR) Market size in the 7MM was estimated to be USD 306.9 Million in 2017 and is anticipated to grow further in the forecast period 2020-30 owing to recent approvals and pipeline therapies.Among the 7MM geographies, the US accounted for the 54% share of the total hATTR ma...

Jan 24, 2019

BridgeBio bags USD 299 Million for genetic diseases BridgeBio Pharma has received a USD299.2 million for its progress in genetic disease pipeline. This includes assets in preclinical and clinical development. Several therapeutic areas are being taken under the consideration of the pharma. Also, th...

Sep 15, 2017

Bayer and Berkeley Lights embark on a project to automate drug discovery Pharmaceutical giant Bayer and Berkeley Lights have announced their collaboration to conduct a strategic project on a discovery platform aimed to automate antibody discovery and development of cell lines. Bayer and Berkeley Lights’ platform- Be...